Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Gabriel N. Hortobagyi

ABSTRACT

Endocrine therapy is recommended for patients with hormone receptor-positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop endocrine resistance. Therefore, it is important to identify treatment options that prolong the effectiveness of first-line endocrine therapies. Ribociclib is an orally bioavailable cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved for use in combination with an aromatase inhibitor for the treatment of HR+, human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This approval is based on findings from the MONALEESA-2 study, a double-blind, placebo-controlled, randomized phase 3 trial (NCT01958021) in which first-line therapy with ribociclib + letrozole significantly improved progression-free survival (PFS) compared with placebo + letrozole in patients with HR+/HER2- advanced breast cancer. This review will discuss the overall findings from the MONALEESA-2 study and will provide a summarized analysis of results from the available subgroups in the study by age, visceral metastases, bone-only disease, de novo disease, and prior therapy. On the basis of these data, ribociclib has established itself as a beneficial treatment option for these different populations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01958021 . Registered on 8 October 2013. More... »

PAGES

123

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13058-018-1050-7

DOI

http://dx.doi.org/10.1186/s13058-018-1050-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107727990

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30340505


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hortobagyi", 
        "givenName": "Gabriel N.", 
        "id": "sg:person.01365732165.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12916-015-0369-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003969537", 
          "https://doi.org/10.1186/s12916-015-0369-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-015-0369-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003969537", 
          "https://doi.org/10.1186/s12916-015-0369-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1607303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005496514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1530/erc-16-0121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005628615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.66.0803", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011569834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.blo.0000093844.72468.f4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013123236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.blo.0000093844.72468.f4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013123236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)32389-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014303949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014894112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024164086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-0931", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027987816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030020773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semradonc.2010.09.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036271148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037043739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860701630234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042232982"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1609709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045557388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13058-016-0721-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050244384", 
          "https://doi.org/10.1186/s13058-016-0721-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13058-016-0721-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050244384", 
          "https://doi.org/10.1186/s13058-016-0721-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr2419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050281960", 
          "https://doi.org/10.1186/bcr2419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71159-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053530404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834015608993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834015608993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0080", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077978564"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0080", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077978564"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.75.6155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092051908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-017-4523-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092334133", 
          "https://doi.org/10.1007/s10549-017-4523-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-017-4523-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092334133", 
          "https://doi.org/10.1007/s10549-017-4523-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-017-4518-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092841000", 
          "https://doi.org/10.1007/s10549-017-4518-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-017-4518-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092841000", 
          "https://doi.org/10.1007/s10549-017-4518-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Endocrine therapy is recommended for patients with hormone receptor-positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop endocrine resistance. Therefore, it is important to identify treatment options that prolong the effectiveness of first-line endocrine therapies. Ribociclib is an orally bioavailable cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved for use in combination with an aromatase inhibitor for the treatment of HR+, human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This approval is based on findings from the MONALEESA-2 study, a double-blind, placebo-controlled, randomized phase 3 trial (NCT01958021) in which first-line therapy with ribociclib + letrozole significantly improved progression-free survival (PFS) compared with placebo + letrozole in patients with HR+/HER2- advanced breast cancer. This review will discuss the overall findings from the MONALEESA-2 study and will provide a summarized analysis of results from the available subgroups in the study by age, visceral metastases, bone-only disease, de novo disease, and prior therapy. On the basis of these data, ribociclib has established itself as a beneficial treatment option for these different populations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01958021 . Registered on 8 October 2013.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13058-018-1050-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1022375", 
        "issn": [
          "1465-5411", 
          "1465-542X"
        ], 
        "name": "Breast Cancer Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial", 
    "pagination": "123", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "99b9acf89491f7fa271796a1e5d21d8788343dbc9d47e1dedb9134fb29f7b0c2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30340505"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100927353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13058-018-1050-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107727990"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13058-018-1050-7", 
      "https://app.dimensions.ai/details/publication/pub.1107727990"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000572.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13058-018-1050-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13058-018-1050-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13058-018-1050-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13058-018-1050-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13058-018-1050-7'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13058-018-1050-7 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N5c908043955d4f17adb3eafee6dfb430
4 schema:citation sg:pub.10.1007/s10549-017-4518-8
5 sg:pub.10.1007/s10549-017-4523-y
6 sg:pub.10.1186/bcr2419
7 sg:pub.10.1186/s12916-015-0369-5
8 sg:pub.10.1186/s13058-016-0721-5
9 https://doi.org/10.1016/j.semradonc.2010.09.001
10 https://doi.org/10.1016/s0140-6736(16)32389-3
11 https://doi.org/10.1016/s1470-2045(14)71159-3
12 https://doi.org/10.1056/nejmoa1607303
13 https://doi.org/10.1056/nejmoa1609709
14 https://doi.org/10.1080/02841860701630234
15 https://doi.org/10.1093/annonc/mdq220
16 https://doi.org/10.1093/annonc/mdu385
17 https://doi.org/10.1097/01.blo.0000093844.72468.f4
18 https://doi.org/10.1158/1078-0432.ccr-06-0931
19 https://doi.org/10.1158/1078-0432.ccr-13-0838
20 https://doi.org/10.1177/1758834015608993
21 https://doi.org/10.1200/jco.2015.66.0803
22 https://doi.org/10.1200/jco.2017.75.6155
23 https://doi.org/10.1530/erc-16-0121
24 https://doi.org/10.3322/caac.21387
25 https://doi.org/10.6004/jnccn.2009.0080
26 schema:datePublished 2018-12
27 schema:datePublishedReg 2018-12-01
28 schema:description Endocrine therapy is recommended for patients with hormone receptor-positive (HR<sup>+</sup>) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop endocrine resistance. Therefore, it is important to identify treatment options that prolong the effectiveness of first-line endocrine therapies. Ribociclib is an orally bioavailable cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved for use in combination with an aromatase inhibitor for the treatment of HR<sup>+</sup>, human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) advanced breast cancer. This approval is based on findings from the MONALEESA-2 study, a double-blind, placebo-controlled, randomized phase 3 trial (NCT01958021) in which first-line therapy with ribociclib + letrozole significantly improved progression-free survival (PFS) compared with placebo + letrozole in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer. This review will discuss the overall findings from the MONALEESA-2 study and will provide a summarized analysis of results from the available subgroups in the study by age, visceral metastases, bone-only disease, de novo disease, and prior therapy. On the basis of these data, ribociclib has established itself as a beneficial treatment option for these different populations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01958021 . Registered on 8 October 2013.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf Naefc128fe1854616925a0c0922a208d7
33 Ncad27e81395d431d9bee54fa62614f03
34 sg:journal.1022375
35 schema:name Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
36 schema:pagination 123
37 schema:productId N44eb668819ac472983a2e26c0cef1059
38 N6f6aa4cd0a904153ae1773283b2b5ce5
39 N9773362b9ff14fd28bd45acb9201a68c
40 Nd68460d97ade42549301af235234c132
41 Neb4e8d79f79f4553b58b3023000da39a
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107727990
43 https://doi.org/10.1186/s13058-018-1050-7
44 schema:sdDatePublished 2019-04-10T21:48
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N38050b19100145f0a3d9bbfbc9ae0c55
47 schema:url https://link.springer.com/10.1186%2Fs13058-018-1050-7
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N38050b19100145f0a3d9bbfbc9ae0c55 schema:name Springer Nature - SN SciGraph project
52 rdf:type schema:Organization
53 N44eb668819ac472983a2e26c0cef1059 schema:name doi
54 schema:value 10.1186/s13058-018-1050-7
55 rdf:type schema:PropertyValue
56 N5c908043955d4f17adb3eafee6dfb430 rdf:first sg:person.01365732165.24
57 rdf:rest rdf:nil
58 N6f6aa4cd0a904153ae1773283b2b5ce5 schema:name pubmed_id
59 schema:value 30340505
60 rdf:type schema:PropertyValue
61 N9773362b9ff14fd28bd45acb9201a68c schema:name dimensions_id
62 schema:value pub.1107727990
63 rdf:type schema:PropertyValue
64 Naefc128fe1854616925a0c0922a208d7 schema:issueNumber 1
65 rdf:type schema:PublicationIssue
66 Ncad27e81395d431d9bee54fa62614f03 schema:volumeNumber 20
67 rdf:type schema:PublicationVolume
68 Nd68460d97ade42549301af235234c132 schema:name readcube_id
69 schema:value 99b9acf89491f7fa271796a1e5d21d8788343dbc9d47e1dedb9134fb29f7b0c2
70 rdf:type schema:PropertyValue
71 Neb4e8d79f79f4553b58b3023000da39a schema:name nlm_unique_id
72 schema:value 100927353
73 rdf:type schema:PropertyValue
74 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
75 schema:name Medical and Health Sciences
76 rdf:type schema:DefinedTerm
77 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
78 schema:name Oncology and Carcinogenesis
79 rdf:type schema:DefinedTerm
80 sg:journal.1022375 schema:issn 1465-5411
81 1465-542X
82 schema:name Breast Cancer Research
83 rdf:type schema:Periodical
84 sg:person.01365732165.24 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
85 schema:familyName Hortobagyi
86 schema:givenName Gabriel N.
87 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24
88 rdf:type schema:Person
89 sg:pub.10.1007/s10549-017-4518-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092841000
90 https://doi.org/10.1007/s10549-017-4518-8
91 rdf:type schema:CreativeWork
92 sg:pub.10.1007/s10549-017-4523-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1092334133
93 https://doi.org/10.1007/s10549-017-4523-y
94 rdf:type schema:CreativeWork
95 sg:pub.10.1186/bcr2419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050281960
96 https://doi.org/10.1186/bcr2419
97 rdf:type schema:CreativeWork
98 sg:pub.10.1186/s12916-015-0369-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003969537
99 https://doi.org/10.1186/s12916-015-0369-5
100 rdf:type schema:CreativeWork
101 sg:pub.10.1186/s13058-016-0721-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050244384
102 https://doi.org/10.1186/s13058-016-0721-5
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1016/j.semradonc.2010.09.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036271148
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1016/s0140-6736(16)32389-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014303949
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1016/s1470-2045(14)71159-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053530404
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1056/nejmoa1607303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005496514
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1056/nejmoa1609709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045557388
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1080/02841860701630234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042232982
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1093/annonc/mdq220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037043739
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1093/annonc/mdu385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024164086
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1097/01.blo.0000093844.72468.f4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013123236
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1158/1078-0432.ccr-06-0931 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027987816
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1158/1078-0432.ccr-13-0838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030020773
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1177/1758834015608993 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077369
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1200/jco.2015.66.0803 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011569834
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1200/jco.2017.75.6155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092051908
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1530/erc-16-0121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005628615
133 rdf:type schema:CreativeWork
134 https://doi.org/10.3322/caac.21387 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014894112
135 rdf:type schema:CreativeWork
136 https://doi.org/10.6004/jnccn.2009.0080 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077978564
137 rdf:type schema:CreativeWork
138 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
139 schema:name Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, 77030, Houston, TX, USA
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...